Li Jing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Li Jing has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hui Guo
Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No 157 West Fifth Road, Xi'an, Shaanxi, 710004, PR China
2 shared publications - Qing Li
Dermatology Hospital, Southern Medical University, Guangzhou 510515, China
2 shared publications Yu Wang
Department of Medical Oncology he First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China
2 shared publicationsHaifeng Sun
The Third Department of Medical Oncology Shaanxi Provincial Tumor Hospital Xi'an China
1 shared publication- Kejun Nan
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University
1 shared publication Lanxuan Huang
Department of Medical Oncology he First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China
1 shared publication
Latest Publications
- 25 March 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (10) , 18448-18458
Epithelial–mesenchymal transition induced cancer‐stem‐cell‐like characteristics in hepatocellular carcinoma
Hepatocellular carcinoma in China accounts for half of the world's incidence. Both epithelial–mesenchymal transition (EMT) and cancer stem cells (CSCs) are thought to be involved in tumor malignant progression. However, the relationship between EMT and CSCs is still unclear. Bioinformatics analysis was performed to evaluate the relationship between EMT and CSCs. The EMT and CSC regulatory mechanism was investigated through Transwell, wound‐healing, sphere formation, colony‐forming, and western blotting assays. Immunofluorescence and immunoprecipitation were used to study the interaction of hypoxia inducible factor 1α (HIF‐1α) /Notch1. Immunohistochemical study was applied to investigate the expression pattern in the process of hepatocellular carcinogenesis and development. In our present study, bioinformatics results indicate that the expression of EMT‐related molecules is correlated with CSCs. In vitro studies indicated that EMT activation could induce CSC characteristics. Notch1 was confirmed to mediate the process of EMT‐induced CSCs through the interaction with HIF‐1α directly. Our findings indicate that EMT could induce CSC‐like characteristics, which is mediated by HIF‐1α‐upregulated Notch intracellular domain expression.
- 25 March 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (10) , 18448-18458
Epithelial–mesenchymal transition induced cancer‐stem‐cell‐like characteristics in hepatocellular carcinoma
Hepatocellular carcinoma in China accounts for half of the world's incidence. Both epithelial–mesenchymal transition (EMT) and cancer stem cells (CSCs) are thought to be involved in tumor malignant progression. However, the relationship between EMT and CSCs is still unclear. Bioinformatics analysis was performed to evaluate the relationship between EMT and CSCs. The EMT and CSC regulatory mechanism was investigated through Transwell, wound‐healing, sphere formation, colony‐forming, and western blotting assays. Immunofluorescence and immunoprecipitation were used to study the interaction of hypoxia inducible factor 1α (HIF‐1α) /Notch1. Immunohistochemical study was applied to investigate the expression pattern in the process of hepatocellular carcinogenesis and development. In our present study, bioinformatics results indicate that the expression of EMT‐related molecules is correlated with CSCs. In vitro studies indicated that EMT activation could induce CSC characteristics. Notch1 was confirmed to mediate the process of EMT‐induced CSCs through the interaction with HIF‐1α directly. Our findings indicate that EMT could induce CSC‐like characteristics, which is mediated by HIF‐1α‐upregulated Notch intracellular domain expression.
- 4 September 2018
- Published by Wiley in Liver International
- Vol. 39 (1) , 147-157
P57‐mediated autophagy promotes the efficacy of EGFR inhibitors in hepatocellular carcinoma
Background & Aims: Resistance to EGFR‐targeted therapy is a major obstacle in hepatocellular carcinoma (HCC) treatment, but its underlying mechanism remains unclear. Autophagy plays a vital role in antitumour treatment. Our previous study suggested that p57 is associated with autophagy and cisplatin resistance. The present study aimed to investigate whether p57 can enhance the sensitivity of HCC cells to Erlotinib (Er)/Cetuximab(C‐225) and further explore the potential mechanisms of Er/C‐225 resistance.Methods: HCC cells were transfected with pIRES2‐EGFP‐p57 and pIRES2‐EGFP‐nc, accompanied by Er/C‐225 treatment. Cell viability was detected by an Annexin apoptosis kit and MTT assay. Xenograft experiments were performed to study the function of p57 in the treatment of Er/C‐225 in vivo. The level of autophagy was determined by analysis of the appearance of autophagic vacuoles. Western blotting was used to investigate the potential pathways involved.Results: Up‐regulation of p57 decreased the level of Er/C‐225‐induced autophagy and enhanced the decrease in Er/C‐225‐induced cell viability. P57 overexpression combined with CQ treatment further enhanced the therapeutic efficiency of Er/C‐225. The xenograft experiment verified that p57 up‐regulation sensitizes HCC cells to Er/C‐225. Moreover, a mechanistic investigation demonstrated that the up‐regulation of p57 resulted in a decrease of LC3B‐II and beclin‐1, and an increase in p‐PI3K, p‐AKT and p‐mTOR protein expressions.Conclusions: Through activating the PI3K/AKT/mTOR signalling pathway, p57 can reverse Er/C‐225‐induced autophagy, and thereby increase the therapeutic efficiency of Er/C‐225 treatment. Given these results, p57 up‐regulation may be applicable as a therapeutic strategy to improve EGFR‐targeted therapy in HCC.
- 4 September 2018
- Published by Wiley in Liver International
- Vol. 39 (1) , 147-157
P57‐mediated autophagy promotes the efficacy of EGFR inhibitors in hepatocellular carcinoma
Background & Aims: Resistance to EGFR‐targeted therapy is a major obstacle in hepatocellular carcinoma (HCC) treatment, but its underlying mechanism remains unclear. Autophagy plays a vital role in antitumour treatment. Our previous study suggested that p57 is associated with autophagy and cisplatin resistance. The present study aimed to investigate whether p57 can enhance the sensitivity of HCC cells to Erlotinib (Er)/Cetuximab(C‐225) and further explore the potential mechanisms of Er/C‐225 resistance.Methods: HCC cells were transfected with pIRES2‐EGFP‐p57 and pIRES2‐EGFP‐nc, accompanied by Er/C‐225 treatment. Cell viability was detected by an Annexin apoptosis kit and MTT assay. Xenograft experiments were performed to study the function of p57 in the treatment of Er/C‐225 in vivo. The level of autophagy was determined by analysis of the appearance of autophagic vacuoles. Western blotting was used to investigate the potential pathways involved.Results: Up‐regulation of p57 decreased the level of Er/C‐225‐induced autophagy and enhanced the decrease in Er/C‐225‐induced cell viability. P57 overexpression combined with CQ treatment further enhanced the therapeutic efficiency of Er/C‐225. The xenograft experiment verified that p57 up‐regulation sensitizes HCC cells to Er/C‐225. Moreover, a mechanistic investigation demonstrated that the up‐regulation of p57 resulted in a decrease of LC3B‐II and beclin‐1, and an increase in p‐PI3K, p‐AKT and p‐mTOR protein expressions.Conclusions: Through activating the PI3K/AKT/mTOR signalling pathway, p57 can reverse Er/C‐225‐induced autophagy, and thereby increase the therapeutic efficiency of Er/C‐225 treatment. Given these results, p57 up‐regulation may be applicable as a therapeutic strategy to improve EGFR‐targeted therapy in HCC.